Xi Yang

Mrs. Xi Yang

Department of Clinical Pharmacy, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Prov-ince, The First Affiliated Hospital, College of Medicine, Zhejiang University
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
XYXi Yang
Xi Yang
MCMei Chen
Mei Chen
XHXiaoying He
Xiaoying He
LHLingjuan He
Lingjuan He
XLXiaoyang Lu
Xiaoyang Lu
YLYan Lou
Yan Lou
Venetoclax has emerged as a breakthrough for treatment of leukemia with a wide interindividual variability in pharmacokinetics. Herein, a rapid, sensitive, and reliable UPLC-MS/MS method for quantification of venetoclax in plasma was developed and validated. The method was operated in the multiple-reaction monitoring (MRM) mode to detect venetoclax at m/z transition 868.5 > 321.0 and IS at 875.5 > 321.0, respectively. Protein precipitation prior to injection into the LC-MS/MS and the analyte was separated on an ACQUITY UPLC BEH C18 column by gradient elution with acetonitrile and 0.1% formic acid in water. Linear calibration curves were obtained in the range of 25–8000 ng/mL. The specificity, recovery, matrix effect, and stability also met the acceptance criteria of FDA guidance. The method was successfully applied to analyze plasma in acute myeloid leukemia (AML) patients. The peak plasma concentration (Cmax) of venetoclax in Chinese AML patient was 2966.0 ± 1595.0 ng/mL while the trough concentration (Cmin) was 1018.0 ± 729.4 ng/mL. Additionally, Cmax and Cmin showed a positive correlation with AST levels. Furthermore, Cmax was significantly higher in the older patients. The present method can be applied for TDM of venetoclax in treatment of hematological cancers.

12 November 2020 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
SLShuanghui Lu
Shuanghui Lu
ZMZhiyuan Ma
Zhiyuan Ma
YGYong Gu
Yong Gu
PLPing Li
Ping Li
YCYingchun Chen
Yingchun Chen
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang

30 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
XHXiaoying He
Xiaoying He
XYXi Yang
Xi Yang
XYXiaoting Yan
Xiaoting Yan
MHMingzhu Huang
Mingzhu Huang
ZXZheng Xiang
Zheng Xiang
YLYan Lou
Yan Lou
The clinical pharmacodynamics of tacrolimus in renal transplant patients has significant interindividual variability. T lymphocytes were selected to study the pharmacodynamic response of tacrolimus, which was significantly correlated with renal function and the outcome of renal transplant patients. Ultra-performance liquid chromatography–quadrupole time-of-flight mass spectroscopy (UPLC/Q-TOF-MS) was performed to obtain the metabolic profiles of 109 renal transplant patients. A partial least squares (PLS) model was constructed to screen potential biomarkers that could predict the efficacy of tacrolimus. Multinomial logistic regression analysis established a bridge that could quantify the relationship between the efficacy of tacrolimus and biomarkers. The results showed a good correlation between endogenous molecules and the efficacy of tacrolimus. Metabolites such as serum creatinine, mesobilirubinogen, L-isoleucine, 5-methoxyindoleacetate, eicosapentaenoic acid, N2-succinoylarginine, tryptophyl-arginine, and butyric acid were indicated as candidate biomarkers. In addition, the key biomarkers could correctly predict the efficacy of tacrolimus with an accuracy of 82.5%. Finally, we explored the mechanism of individual variation by pathway analysis, which showed that amino acid metabolism was significantly related to the efficacy of tacrolimus. Moreover, orthogonal partial least squares discriminant analysis (OPLS-DA) showed that there was no difference in key metabolites among different pharmacodynamic groups at 1 month and 3 months after dose adjustment, suggesting that pharmacometabonomics is a useful tool to predict individual differences in pharmacodynamics and thus to facilitate individualized drug therapy.